After rebates, Johnson & Johnson says prices fell 4.6% last year

In a report highlighting the company’s record on corporate responsibility, Johnson & Johnson (NYSE: JNJ) notes that the average list price increase for its medications was in the single-digit percentages last year.

Prescription medications rose by an average of 8.1%, a little higher than the year before, although the company says that, after discounts and rebates, prices actually fell by 4.6% in the USA.

The company started issuing a “Transparency Report” last year, with the aim of “increasing transparency around the pricing of medication and other topics related to value and access for patients, consumers, healthcare professionals and policymakers.”